2g/Day of DHA for 2 Years Has No Impact on Cognition or Hippocampal Volume (PreventE4)

Key Takeaways

• 2 g/day DHA raised CSF DHA/AA ratio significantly.
• No difference in hippocampal volume or cortical thickness after 24 months.
• Cognitive scores unchanged; both groups improved modestly.
• 38 % dropout, mainly COVID‑19 related.
• Findings question DHA’s preventive role despite target engagement.

Pulse Analysis

The PreventE4 study is the first large‑scale, double‑blind trial to test whether high‑dose DHA can stave off Alzheimer’s pathology in cognitively normal APOE ε4 carriers. Over 24 months, participants received 2 g of DHA daily, which boosted the cerebrospinal fluid DHA‑to‑arachidonic‑acid ratio by 0.19 units—a clear sign of target engagement. However, magnetic‑resonance imaging showed no meaningful change in hippocampian volume or cortical thickness, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) revealed no treatment‑specific cognitive benefit. The trial’s 38 % attrition, driven largely by the COVID‑19 pandemic, further limits the precision of the findings.

The null structural and cognitive results contrast sharply with decades of epidemiologic work linking higher omega‑3 index values—typically above 8 %—to reduced cardiovascular and brain‑aging risk. Those observational associations often rely on total EPA + DHA levels, yet recent Mendelian randomization studies suggest EPA may drive the protective signal, while DHA alone shows weaker or inconsistent effects. Moreover, the omega‑3 index’s therapeutic windows of < 4 % and > 8 % were derived from coronary‑heart disease cohorts, not Alzheimer’s trials, raising questions about a one‑size‑fits‑all target.

For supplement manufacturers and clinicians, PreventE4 delivers a cautionary note: simply raising brain DHA concentrations does not guarantee disease modification. The findings revive interest in multimodal nutrition strategies that combine EPA‑rich fish oil, B‑vitamins, choline, or marine carotenoids—components naturally present in whole‑fish diets. Guideline committees may now weigh the cost‑effectiveness of DHA‑only products against broader dietary recommendations. Future research should explore synergistic nutrient blends, longer follow‑up periods, and stratified analyses by baseline omega‑3 status to clarify who, if anyone, can benefit from DHA supplementation.